Published in Depress Anxiety on December 18, 2013
University of Iowa Interventional Psychiatry Service Patient Registry | NCT04480918
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res (2014) 1.09
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis (2015) 0.98
Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord (2014) 0.90
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol (2014) 0.87
The neuroscience of depression: implications for assessment and intervention. Behav Res Ther (2014) 0.83
Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.81
Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialogues Clin Neurosci (2014) 0.80
Cortical abnormalities and association with symptom dimensions across the depressive spectrum. J Affect Disord (2015) 0.80
Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. J Affect Disord (2014) 0.80
Attachment Style Moderates the Effects of Oxytocin on Social Behaviors and Cognitions During Social Rejection: Applying an RDoC Framework to Social Anxiety. Clin Psychol Sci (2014) 0.80
Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord (2014) 0.80
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry (2016) 0.77
Biological predictors of pharmacological therapy in anxiety disorders. Dialogues Clin Neurosci (2015) 0.76
Animal models to improve our understanding and treatment of suicidal behavior. Transl Psychiatry (2017) 0.76
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs (2017) 0.75
Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol Psychiatry (2017) 0.75
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry (2010) 16.89
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Systems biology: a brief overview. Science (2002) 14.69
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Antidepressants and the risk of suicidal behaviors. JAMA (2004) 7.08
Bring on the biomarkers. Nature (2011) 5.77
Cingulate function in depression: a potential predictor of treatment response. Neuroreport (1997) 4.48
Suicide risk during antidepressant treatment. Am J Psychiatry (2006) 4.41
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Data sharing in neuroimaging research. Front Neuroinform (2012) 2.92
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry (2007) 2.66
Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry (2007) 2.20
The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology (2011) 2.18
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer (2005) 2.12
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol (2008) 2.01
Is pharma running out of brainy ideas? Science (2010) 1.99
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry (2013) 1.44
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers (2009) 1.37
Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol (2008) 1.35
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry (2011) 1.27
Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull (2007) 1.24
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
2012 FDA drug approvals. Nat Rev Drug Discov (2013) 1.14
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Translational medicine and the value of biomarker qualification. Sci Transl Med (2010) 1.12
Human biomarkers of rapid antidepressant effects. Biol Psychiatry (2013) 1.09
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom (2010) 1.07
The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol (2008) 1.05
Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry (2013) 1.02
Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry (2011) 1.00
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord (2012) 0.95
Using computational patients to evaluate illness mechanisms in schizophrenia. Biol Psychiatry (2011) 0.95
Defining response in migraine: which endpoints are important? Eur Neurol (2005) 0.91
Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study. Biol Psychiatry (2011) 0.90
Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl) (1982) 0.85
Pharmacogenetically driven treatments for alcoholism: are we there yet? CNS Drugs (2012) 0.84
Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin Neurosci (2006) 0.83
Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease. J Dig Dis (2012) 0.83
Translation of neurological biomarkers to clinically relevant platforms. Methods Mol Biol (2009) 0.82
Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. Neuropsychopharmacology (2013) 0.80
Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol (2011) 0.80
Toward a systems biology of mood disorder. Biol Psychiatry (2013) 0.79
Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy. Adv Exp Med Biol (2012) 0.79
Psychiatric systems medicine: closer at hand than anticipated but not with the expected portrait. Pharmacopsychiatry (2012) 0.78
A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin (1999) 0.78
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J Psychopharmacol (2013) 0.78
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct (2008) 6.32
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
Beyond sensory images: Object-based representation in the human ventral pathway. Proc Natl Acad Sci U S A (2004) 1.76
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry (2010) 1.66
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Neural basis of abnormal response to negative feedback in unmedicated mood disorders. Neuroimage (2008) 1.37
Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry (2005) 1.37
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry (2012) 1.27
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry (2003) 1.25
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. Am J Psychiatry (2012) 1.21
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp (2012) 1.14
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2008) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry (2004) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry (2012) 1.12
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2010) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. Bipolar Disord (2012) 1.11
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
Human biomarkers of rapid antidepressant effects. Biol Psychiatry (2013) 1.09
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry (2012) 1.09
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Reduced posterior hippocampal volume in posttraumatic stress disorder. J Clin Psychiatry (2008) 1.08
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Letter to the editor in response to 2012 article by Frances and Jones. Bipolar Disord (2014) 1.07
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 1.06
The underlying neurobiology of bipolar disorder. World Psychiatry (2003) 1.05
Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry (2012) 1.05
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Performance on a virtual reality spatial memory navigation task in depressed patients. Am J Psychiatry (2007) 1.03